John Crowley, Chairman and CEO, Featured on CNBC
Amicus Chairman and Chief Executive Officer John Crowley says treatment for Pompe disease could be the crown jewel of the company. View video.
Enrique Diloné, Senior VP of Technical Operations, Featured in pharmaVOICE Supply Chain Report
Dr. Diloné discusses the unique and complex challenges in getting a therapy to geographically dispersed rare disease patients. View article.
Amicus Pauses for Pompe
We did the #PauseForPompe challenge to raise awareness for those living with Pompe disease in honor of International Pompe Day, April 15th!
Amicus Hosts CabaRare
Our CabaRare showcase featured entertainers living with rare diseases in honor of Rare Disease Day 2017.
Amicus COO Bradley Campbell Featured in PharmaVOICE
Mr. Campbell discusses how engagement with rare disease advocacy groups has helped Amicus build trust with patients and families. View article.
Biotechnology requires massive investment: CEO John Crowley
John Crowley, CEO of Amicus Therapeutics, discusses his biotechnology business model, as well as drugs pricing.
Amicus Therapeutics (FOLD) CEO John Crowley 'Squawk Box' on CNBC
Amicus Therapeutics CEO: Driving science to a cure
John Crowley, Amicus Therapeutics chairman and CEO, discusses its Fabry pill development and next generation therapy for Pompe disease, with CNBC's Jim Cramer.
One Dad’s 14-Year Quest for Cure
By GEETA ANAND
Seven months ago, Megan Crowley made a gutsy decision: to undergo a radical surgery to straighten out her spine, which has been crippled by Pompe disease. Photo: Lexey Swall